Kaiser Foundation Hospitals and Medpace took part in a round that will support phase 3 trials for the startup's lead cardiometabolic disease drug candidate.

Illumina Ventures and AV8 Ventures returned for a series A round that will push the startup's liquid biopsy technology towards the clinical trial stage.

The transistor technology developer has disclosed $21.8m in series A funding from investors including Agilent Technologies across three tranches.

Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.

Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.

Existing investor SoftBank Ventures Asia helped the online investment platform developer close a round that will fund its growth in Indonesia.

Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

ADM Ventures, GV and Barclays helped the microbe-based protein developer close a round that will support research and development.

The newly launched cancer therapy startup plans to initiate clinical trials this year after securing funding from Alexandria Real Estate Equities’ venture arm.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.